HEPACAM2 antibody is human, mouse and rat reactive. At least two isoforms of HEPACAM2 are known to exist, this antibody will detect both isoforms. HEPACAM2 antibody is predicted to not cross-react with HEPACAM.
Purification
HEPACAM2 Antibody is affinity chromatography purified via peptide column.
Immunogen
Rabbit polyclonal HEPACAM2 antibody was raised against a 19 amino acid peptide near the carboxy terminus of human HEPACAM2. The immunogen is located within amino acids 370 - 420 of HEPACAM2.
HEPACAM2
Reactivity: Human
ELISA, WB
Host: Rabbit
Polyclonal
unconjugated
Application Notes
HEPACAM2 antibody can be used for detection of HEPACAM2 by Western blot at 0.5 - 1 μ,g/mL.
Antibody validated: Western Blot in mouse samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
HEPACAM2 Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
HEPACAM2 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
MIKI antibody, AI987662 antibody, RGD1305697 antibody, HEPACAM family member 2 antibody, HEPACAM2 antibody, Hepacam2 antibody
Background
HEPACAM2 Antibody: HEPACAM2 (Hepatocyte cell adhesion molecule 2), a type I N-linked transmembrane glycoprotein, belongs to the immunoglobulin superfamily. The exact function of HEPACAM2 is currently unknown, but the related protein HEPACAM forms cishomodimers on the cell surface to regulate the cell adhesion and may inhibit cell growth through suppression of cell proliferation. HEPACAM and HEPACAM2 mRNA are differentially regulated in canine tumors, with HEPACAM2 mRNA showing increased levels in adenomas, but decreased levels in metastatic carcinomas compared to normal tissues, while HEPACAM protein levels decreased in adenomas. It is therefore likely that HEPACAM2 plays a different role than HEPACAM in the development and progression to tumors.